Repligen Corp (RGEN)
120.16
-3.16
(-2.56%)
USD |
NASDAQ |
Jul 02, 16:00
122.47
+2.31
(+1.92%)
After-Hours: 20:00
Repligen Research and Development Expense (TTM): 41.81M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 41.81M |
| December 31, 2023 | 42.72M |
| September 30, 2023 | 43.55M |
| June 30, 2023 | 43.20M |
| March 31, 2023 | 43.94M |
| December 31, 2022 | 43.94M |
| September 30, 2022 | 41.94M |
| June 30, 2022 | 40.87M |
| March 31, 2022 | 38.82M |
| December 31, 2021 | 34.27M |
| September 30, 2021 | 31.88M |
| June 30, 2021 | 27.14M |
| March 31, 2021 | 23.09M |
| December 31, 2020 | 20.18M |
| September 30, 2020 | 18.63M |
| June 30, 2020 | 19.64M |
| March 31, 2020 | 20.53M |
| December 31, 2019 | 19.45M |
| September 30, 2019 | 17.43M |
| June 30, 2019 | 15.60M |
| March 31, 2019 | 16.15M |
| December 31, 2018 | 15.82M |
| September 30, 2018 | 15.74M |
| June 30, 2018 | 14.14M |
| March 31, 2018 | 10.22M |
| Date | Value |
|---|---|
| December 31, 2017 | 8.672M |
| September 30, 2017 | 7.642M |
| June 30, 2017 | 7.527M |
| March 31, 2017 | 7.557M |
| December 31, 2016 | 7.354M |
| September 30, 2016 | 6.746M |
| June 30, 2016 | 6.35M |
| March 31, 2016 | 5.712M |
| December 31, 2015 | 5.741M |
| September 30, 2015 | 5.638M |
| June 30, 2015 | 5.798M |
| March 31, 2015 | 5.976M |
| December 31, 2014 | 5.609M |
| September 30, 2014 | 5.703M |
| June 30, 2014 | 5.482M |
| March 31, 2014 | 6.359M |
| December 31, 2013 | 7.341M |
| September 30, 2013 | 8.262M |
| June 30, 2013 | 9.265M |
| March 31, 2013 | 9.865M |
| December 31, 2012 | 10.49M |
| September 30, 2012 | 11.22M |
| June 30, 2012 | 12.31M |
| March 31, 2012 | 13.18M |
| September 30, 2011 | 13.31M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
17.43M
Minimum
Sep 2019
43.94M
Maximum
Dec 2022
32.26M
Average
34.27M
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Perspective Therapeutics Inc | 24.91M |
| Retractable Technologies Inc | 0.5937M |
| Xtant Medical Holdings Inc | 1.689M |
| Asensus Surgical Inc | 34.98M |
| Catheter Precision Inc | 0.272M |